Enzon Pharmaceuticals, Inc. Share Price

Equities

ENZN

US2939041081

Biotechnology & Medical Research

Market Closed - OTC Markets 11:03:31 26/04/2024 pm IST 5-day change 1st Jan Change
0.0834 USD -5.17% Intraday chart for Enzon Pharmaceuticals, Inc. +15.33% -10.79%
Sales 2022 26K 2.17M Sales 2023 - Capitalization 6.94M 579M
Net income 2022 - 0 Net income 2023 1M 83.38M EV / Sales 2022 -1,103 x
Net cash position 2022 46.98M 3.92B Net cash position 2023 47.01M 3.92B EV / Sales 2023 -
P/E ratio 2022
-12.5 x
P/E ratio 2023
70.9 x
Employees 1
Yield 2022 *
-
Yield 2023
-
Free-Float 89.16%
More Fundamentals * Assessed data
Dynamic Chart
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Enzon Pharmaceuticals, Inc. Announces Executive Changes CI
Enzon Pharmaceuticals, Inc. Appoints Richard L. Feinstein as Secretary CI
More news
1 day-5.17%
1 week+15.33%
Current month-11.64%
1 month-1.18%
3 months-1.88%
6 months-44.26%
Current year-10.79%
More quotes
1 week
0.07
Extreme 0.072
0.09
1 month
0.06
Extreme 0.06
0.10
Current year
0.06
Extreme 0.06
0.12
1 year
0.06
Extreme 0.06
0.22
3 years
0.06
Extreme 0.06
0.76
5 years
0.02
Extreme 0.02
0.85
10 years
0.02
Extreme 0.02
1.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 80 13/13/13
Members of the board TitleAgeSince
Chairman 71 04/20/04
Director/Board Member 67 01/22/01
Director/Board Member 68 04/20/04
More insiders
Date Price Change Volume
26/24/26 0.0834 -5.17% 900
25/24/25 0.088 +12.87% 3,991

Delayed Quote OTC Markets, April 26, 2024 at 11:03 pm IST

More quotes
Enzon Pharmaceuticals, Inc. (Enzon) is an acquisition vehicle company. The Company intends to become an acquisition platform. The Company utilizes its net operating loss carryforwards (NOLs) and improves stockholder value. It manages its source of royalty revenues from existing licensing arrangements with other companies.
More about the company